> top > docs > PMC:7537941 > spans > 18822-19127 > annotations

PMC:7537941 / 18822-19127 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T138 286-294 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T139 295-304 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T184 91-94 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T185 126-127 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T186 224-225 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T187 235-236 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
564 40-47 Species denotes patient Tax:9606
580 286-304 Disease denotes COVID-19 pneumonia MESH:C000657245

MyTest

Id Subject Object Predicate Lexical cue
33004529-23826709-29393028 196-198 23826709 denotes 68

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T77 295-304 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090

2_test

Id Subject Object Predicate Lexical cue
33004529-23826709-29393028 196-198 23826709 denotes 68

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T106 0-305 Sentence denotes However, the significant differences in patient characteristics between the PROWESS trials has led to the recommendation that a trial of DrotAA should be repeated using an optimised study design [68], and this could include a trial in a less heterogeneous high-risk population, such as COVID-19 pneumonia.